Moligo Technologies

Executive Summary

Moligo Technologies is a Swedish biotechnology company founded in 2019 that has developed a proprietary enzymatic synthesis platform capable of producing ultrapure, long single-stranded DNA (ssDNA) up to 10 kilobases at industrial scale. This technology addresses critical limitations in existing DNA manufacturing methods, such as chemical synthesis and PCR, which struggle with length, purity, and scalability. The company's ssDNA products are designed to enable safer and more effective gene therapies, CRISPR gene editing, and synthetic biology applications. By providing high-quality DNA starting materials, Moligo aims to accelerate the development of advanced gene-based therapeutics and reduce costs. The company is privately held and based in Stockholm, Sweden, with a strong focus on serving the growing demand for long ssDNA in the biopharma industry.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a leading gene therapy developer for ssDNA supply60% success
• Q4 2026Completion of Series B funding round to scale manufacturing70% success
• Q2 2026Publication of peer-reviewed data demonstrating ssDNA performance in CRISPR editing50% success